Literature DB >> 17202224

Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.

Yana Kiselyeva1, Rebecca Nedellec, Alejandra Ramos, Cristina Pastore, Leonid B Margolis, Donald E Mosier.   

Abstract

CCR5-using human immunodeficiency virus type 1 (HIV-1) isolates typically gain CXCR4 use via multiple mutations in V3 and often V1/V2 regions of envelope, and patterns of mutations are distinct for each isolate. Here, we report that multiple CXCR4-using variants of a parental CCR5-using HIV-1 isolate, SF162, obtained by either target cell selection or CCR5 inhibition have a common mutation pattern characterized by the same two V3 mutations and that these mutations preexisted in some of the SF162 stocks. These results imply that SF162 has a single pathway for acquiring CXCR4 use and that prolonged culture is sufficient to select for R5X4 variants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202224      PMCID: PMC1866070          DOI: 10.1128/JVI.02310-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; A Cara; R C Gallo; P Lusso
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

2.  Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells.

Authors:  A Carrillo; L Ratner
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

3.  Relation of phenotype evolution of HIV-1 to envelope V2 configuration.

Authors:  M Groenink; R A Fouchier; S Broersen; C H Baker; M Koot; A B van't Wout; H G Huisman; F Miedema; M Tersmette; H Schuitemaker
Journal:  Science       Date:  1993-06-04       Impact factor: 47.728

4.  Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation.

Authors:  C Cheng-Mayer; M Quiroga; J W Tung; D Dina; J A Levy
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.

Authors:  S L Kozak; E J Platt; N Madani; F E Ferro; K Peden; D Kabat
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.

Authors:  G Harrowe; C Cheng-Mayer
Journal:  Virology       Date:  1995-07-10       Impact factor: 3.616

7.  Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

8.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Distinct biological and serological properties of human immunodeficiency viruses from the brain.

Authors:  C Cheng-Mayer; J A Levy
Journal:  Ann Neurol       Date:  1988       Impact factor: 10.422

10.  A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus.

Authors:  S A Bozzette; J A McCutchan; S A Spector; B Wright; D D Richman
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

View more
  9 in total

1.  Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.

Authors:  Boris Julg; Amarendra Pegu; Peter Abbink; Jinyan Liu; Amanda Brinkman; Katherine Molloy; Shanell Mojta; Abishek Chandrashekar; Katherine Callow; Keyun Wang; Xuejun Chen; Stephen D Schmidt; Jinghe Huang; Richard A Koup; Michael S Seaman; Brandon F Keele; John R Mascola; Mark Connors; Dan H Barouch
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

2.  Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.

Authors:  Thomas van Stigt Thans; Janet I Akko; Annika Niehrs; Wilfredo F Garcia-Beltran; Laura Richert; Christina M Stürzel; Christopher T Ford; Hui Li; Christina Ochsenbauer; John C Kappes; Beatrice H Hahn; Frank Kirchhoff; Glòria Martrus; Daniel Sauter; Marcus Altfeld; Angelique Hölzemer
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

3.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

4.  Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.

Authors:  Wuze Ren; Silvana Tasca; Ke Zhuang; Agegnehu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

5.  Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques.

Authors:  Siu-hong Ho; Silvana Tasca; Lili Shek; Amy Li; Agegnehu Gettie; James Blanchard; Daniel Boden; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

6.  Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype.

Authors:  R Nedellec; M Coetzer; N Shimizu; H Hoshino; V R Polonis; L Morris; U E A Mårtensson; J Binley; J Overbaugh; D E Mosier
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

7.  Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.

Authors:  Rebecca Nedellec; Mia Coetzer; Michael M Lederman; Robin E Offord; Oliver Hartley; Donald E Mosier
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

Review 8.  Coreceptor use in nonhuman primate models of HIV infection.

Authors:  Silvana Tasca Sina; Wuze Ren; Cecilia Cheng-Mayer
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

9.  Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies.

Authors:  Marco Salemi; Brant R Burkhardt; Rebecca R Gray; Guity Ghaffari; John W Sleasman; Maureen M Goodenow
Journal:  PLoS One       Date:  2007-09-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.